MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

MDT

88.62

+1.08%↑

VEEV

280.06

-0.3%↓

A

121.12

+1.59%↑

WBA

11.52

0%↓

HQY

103.04

+1.28%↑

Search

Emergent BioSolutions Inc

Closed

SectorHealthcare

6.88 3.61

Overview

Share price change

24h

Current

Min

6.68

Max

6.92

Key metrics

By Trading Economics

Income

99M

68M

Sales

33M

222M

Profit margin

30.603

Employees

900

EBITDA

120M

133M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+103.93% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

62M

379M

Previous open

3.27

Previous close

6.88

News Sentiment

By Acuity

67%

33%

335 / 376 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Emergent BioSolutions Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Jul 2025, 19:37 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

M3-Brigade Shares Fall on Merger With ReserveOne

8 Jul 2025, 23:45 UTC

Market Talk

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 Jul 2025, 23:42 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

8 Jul 2025, 23:27 UTC

Market Talk

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 Jul 2025, 23:27 UTC

Market Talk

Global Equities Roundup: Market Talk

8 Jul 2025, 23:21 UTC

Market Talk

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 Jul 2025, 23:21 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 Jul 2025, 22:29 UTC

Acquisitions, Mergers, Takeovers

Capricorn to Pay A$1.5 Million in Cash and Shares

8 Jul 2025, 22:28 UTC

Acquisitions, Mergers, Takeovers

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 Jul 2025, 21:58 UTC

Market Talk

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 Jul 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 Jul 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 Jul 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 Jul 2025, 19:53 UTC

Market Talk

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 Jul 2025, 19:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

8 Jul 2025, 19:45 UTC

Market Talk

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 Jul 2025, 19:29 UTC

Market Talk

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 Jul 2025, 19:20 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 Jul 2025, 19:11 UTC

Market Talk

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 Jul 2025, 19:01 UTC

Market Talk

Oil Futures Gain With Support From Products -- Market Talk

8 Jul 2025, 18:49 UTC

Earnings

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 Jul 2025, 18:41 UTC

Market Talk

Mexico's Inflation Seen Mixed in June -- Market Talk

8 Jul 2025, 18:38 UTC

Market Talk

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 Jul 2025, 18:23 UTC

Market Talk

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 Jul 2025, 18:10 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

8 Jul 2025, 18:10 UTC

Market Talk

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 Jul 2025, 17:24 UTC

Market Talk

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 Jul 2025, 17:06 UTC

Market Talk

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 Jul 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Emergent BioSolutions Inc Forecast

Price Target

By TipRanks

103.93% upside

12 Months Forecast

Average 13.5 USD  103.93%

High 15 USD

Low 12 USD

Based on 2 Wall Street analysts offering 12 month price targets forEmergent BioSolutions Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.95 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

335 / 376 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.